Last update 20 Mar 2025

ABX002(Boehringer Ingelheim)

Overview

Basic Info

Drug Type
Antibody
Synonyms-
Target
HLA-E x NKG2A
Action
modulators, antagonists
Mechanism
HLA-E modulators(major histocompatibility complex, class I, E modulators), NKG2A antagonists(killer cell lectin like receptor C1 antagonists)
Therapeutic Areas
Neoplasms
Active Indication
Neoplasms
Inactive Indication-
Originator Organization
Abexxa Biologics, Inc.Abexxa Biologics, Inc.StartupBoehringer Ingelheim Pharmaceuticals, Inc.The University of Texas at ArlingtonThe University of Texas at Arlington
Active Organization
The University of Texas at ArlingtonThe University of Texas at ArlingtonAbexxa Biologics, Inc.Abexxa Biologics, Inc.StartupBoehringer Ingelheim Pharmaceuticals, Inc.
Inactive Organization-
Drug Highest PhasePreclinical
First Approval Date-
Regulation-

Related

100 Clinical Results associated with ABX002(Boehringer Ingelheim)
Login to view more data
100 Translational Medicine associated with ABX002(Boehringer Ingelheim)
Login to view more data
100 Patents (Medical) associated with ABX002(Boehringer Ingelheim)
Login to view more data
1
Literatures (Medical) associated with ABX002(Boehringer Ingelheim)
04 Jan 2010Inorganic ChemistryQ2 · CHEMISTRY
Playing the Quantum Chemical Slot Machine: An Exploration of ABX2 Compounds
Q2 · CHEMISTRY
100 Deals associated with ABX002(Boehringer Ingelheim)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
NeoplasmsPreclinical
United States
Boehringer Ingelheim Pharmaceuticals, Inc.
05 Nov 2024
NeoplasmsPreclinical
United States
Abexxa Biologics, Inc.Abexxa Biologics, Inc.Startup
05 Nov 2024
NeoplasmsPreclinical
United States
The University of Texas at ArlingtonThe University of Texas at Arlington
05 Nov 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
view full example data
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free